TY - JOUR T1 - Acceleration of chemical shift encoding-based water fat MRI for liver proton density fat fraction and T2* mapping using compressed sensing JF - medRxiv DO - 10.1101/19000927 SP - 19000927 AU - Fabian K. Lohöfer AU - Georgios A. Kaissis AU - Christina Müller-Leisse AU - Daniela Franz AU - Christoph Katemann AU - Andreas Hock AU - Johannes M. Peeters AU - Ernst J. Rummeny AU - Dimitrios Karampinos AU - Rickmer F. Braren Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/07/03/19000927.abstract N2 - Objectives To evaluate proton density fat fraction (PDFF) and T2* measurements of the liver with combined parallel imaging (sensitivity encoding, SENSE) and compressed sensing (CS) accelerated chemical shift encoding-based water-fat separation.Methods Six-echo Dixon imaging was performed in the liver of 89 subjects. The first acquisition variant used acceleration based on SENSE with a total acceleration factor equal to 2.64 (acquisition labeled as SENSE). The second acquisition variant used acceleration based on a combination of CS with SENSE with a total acceleration factor equal to 4 (acquisition labeled as CS+SENSE). Acquisition times were compared between acquisitions and proton density fat fraction (PDFF) and T2*-values were measured and compared separately for each liver segment.Results Total scan duration was 14.5 sec for the SENSE accelerated image acquisition and 9.3 sec for the CS+SENSE accelerated image acquisition. PDFF and T2* values did not differ significantly between the two acquisitions (paired Mann-Whitney and paired t-test P>0.05 in all cases). CS+SENSE accelerated acquisition showed reduced motion artifacts (1.1%) compared to SENSE acquisition (12.3%).Conclusion CS+SENSE accelerates liver PDFF and T2*mapping while retaining the same quantitative values as an acquisition using only SENSE and reduces motion artifacts.Strengths of this studyCompressed sensing allows accelerated imaging with reduction of motion artifacts without alteration of quantitative measurementsRobust results in fat and iron quantification in a heterogeneous patient cohortLimitations of this studyNo histopathological validation of the MR findings was performedThe study was not performed at different field strengthsCompeting Interest StatementThe authors acknowledge research support from Philips Healthcare Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.NAI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe data generated during the study is available from the corresponding author on reasonable request by a qualified individual or third-party, subject to authorization of pertinent regulatory bodies. ER -